These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 10870640

  • 1. Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-beta-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5'-->5')-N4-octadecyl-1-beta-D-arabinofuranosylcytosi ne.
    Horber DH, Cattaneo-Pangrazzi RM, von Ballmoos P, Schott H, Ludwig PS, Eriksson S, Fichtner I, Schwendener RA.
    J Cancer Res Clin Oncol; 2000 Jun; 126(6):311-9. PubMed ID: 10870640
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145.
    Cattaneo-Pangrazzi RM, Schott H, Schwendener RA.
    Prostate; 2000 Sep 15; 45(1):8-18. PubMed ID: 10960838
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Stimulation of 1-(beta-D-arabinofuranosyl)cytosine (AraC)-induced apoptosis in the multidrug resistant human promyelocytic leukemia cell lines with protein kinase inhibitors.
    Hunáková L, Suliková M, Duraj J, Sedlák J, Chorváth B.
    Neoplasma; 1996 Sep 15; 43(5):291-5. PubMed ID: 8996546
    [Abstract] [Full Text] [Related]

  • 7. Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model.
    Schwendener RA, Schott H.
    J Cancer Res Clin Oncol; 1996 Sep 15; 122(12):723-6. PubMed ID: 8954169
    [Abstract] [Full Text] [Related]

  • 8. Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.
    Horber DH, Schott H, Schwendener RA.
    Cancer Chemother Pharmacol; 1995 Sep 15; 36(6):483-92. PubMed ID: 7554040
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine.
    Horber DH, Schott H, Schwendener RA.
    Br J Cancer; 1995 May 15; 71(5):957-62. PubMed ID: 7734320
    [Abstract] [Full Text] [Related]

  • 11. Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine.
    Schwendener RA, Horber DH, Odermatt B, Schott H.
    J Cancer Res Clin Oncol; 1996 May 15; 122(2):102-8. PubMed ID: 8576276
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug.
    Koller-Lucae SK, Schott H, Schwendener RA.
    J Pharmacol Exp Ther; 1997 Sep 15; 282(3):1572-80. PubMed ID: 9316874
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine.
    Niitsu N, Ishii Y, Matsuda A, Honma Y.
    Cancer Res; 2001 Jan 01; 61(1):178-85. PubMed ID: 11196157
    [Abstract] [Full Text] [Related]

  • 17. Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in Daudi lymphoma cells.
    Koller-Lucae SK, Schott H, Schwendener RA.
    Br J Cancer; 1999 Jul 01; 80(10):1542-9. PubMed ID: 10408395
    [Abstract] [Full Text] [Related]

  • 18. Analysis of mechanisms contributing to AraC-mediated chemoresistance and re-establishment of drug sensitivity by the novel heterodinucleoside phosphate 5-FdUrd-araC.
    Maier S, Strasser S, Saiko P, Leisser C, Sasgary S, Grusch M, Madlener S, Bader Y, Hartmann J, Schott H, Mader RM, Szekeres T, Fritzer-Szekeres M, Krupitza G.
    Apoptosis; 2006 Mar 01; 11(3):427-40. PubMed ID: 16538382
    [Abstract] [Full Text] [Related]

  • 19. Lipophilic arabinofuranosyl cytosine derivatives in liposomes.
    Schwendener R, Schott H.
    Methods Enzymol; 2005 Mar 01; 391():58-70. PubMed ID: 15721374
    [Abstract] [Full Text] [Related]

  • 20. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
    Hanaoka K, Suzuki M, Kobayashi T, Tanzawa F, Tanaka K, Shibayama T, Miura S, Ikeda T, Iwabuchi H, Nakagawa A, Mitsuhashi Y, Hisaoka M, Kaneko M, Tomida A, Wataya Y, Nomura T, Sasaki T, Matsuda A, Tsuruo T, Kurakata S.
    Int J Cancer; 1999 Jul 19; 82(2):226-36. PubMed ID: 10389757
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.